SCHEMBL29555802

SCHEMBL29555802

CCCCN(Cc1ccccc1Br)C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.50
ERBB2 P04626 1/20 0.46
SSTR4 P31391 1/20 0.45
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 2/20 0.42
HDAC1 Q13547 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC2 Q92769 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
RIPK1 Q13546 1/20 0.40
NFKB1 P19838 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 3/20 0.39
BLM P54132 1/20 0.39
PKM P14618 1/20 0.39
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4718059 0.90 SSTR4 (0.50) EGFRERBB2SSTR4CYP1A2CYP2D6
SCHEMBL13168302 0.84 SSTR4 (0.45) SSTR4CYP1A2CYP2D6CYP2C19TSHR
SCHEMBL13166749 0.84 SSTR4 (0.45) EGFRSSTR4CYP1A2CYP2D6CYP2C19
SCHEMBL6383048 0.82 EGFR (0.58) EGFRERBB2CYP1A2CYP2D6CYP2C19
SCHEMBL29555606 0.81 CNR2 (0.43) EGFRERBB2CYP1A2CYP2D6CYP2C19
SCHEMBL7057723 0.80 BCHE (0.46)
SCHEMBL12062379 0.80 HDAC1 (0.47) SSTR4HDAC1HDAC3HDAC2NCOR2
SCHEMBL4719975 0.79 GPR52 (0.41) EGFRSSTR4CYP1A2CYP2D6CYP2C19
SCHEMBL4719978 0.79 GPR52 (0.41) EGFRSSTR4CYP1A2CYP2D6CYP2C19
SCHEMBL15261600 0.77 HTR2C (0.43) SSTR4CYP1A2CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 US disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 EP disclosed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 EGFR 3433/4885ERBB2 3060/4885SSTR4 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.